[S-8 POS] Turnstone Biologics Corp. SEC Filing
Turnstone Biologics Corp. has filed post-effective amendments to withdraw and deregister all unsold shares that remained registered under two Form S-8 registration statements. The company removed a total of 7,003,706 unsold shares from registration, representing shares reserved under its 2018 Equity Incentive Plan, 2023 Equity Incentive Plan and 2023 Employee Stock Purchase Plan.
The deregistration follows a merger agreement under which Turnstone became a wholly owned subsidiary of XOMA Royalty Corporation, with XRA 3 Corp. as merger sub. As a result, the Registrant terminated the offerings contemplated by the S-8 registration statements and removed the unsold shares from registration as required by its prior undertakings. The post-effective amendments were signed by Owen Hughes, President, Treasurer and Secretary.
Turnstone Biologics Corp. ha depositato emendamenti successivi all'efficacia per ritirare e cancellare dalla registrazione tutte le azioni invendute che risultavano ancora registrate in due dichiarazioni di registrazione sul Modulo S-8. La società ha rimosso complessivamente 7,003,706 azioni invendute dalla registrazione, corrispondenti a titoli riservati nei suoi piani 2018 Equity Incentive Plan, 2023 Equity Incentive Plan e 2023 Employee Stock Purchase Plan.
La cancellazione dalla registrazione segue un accordo di fusione in base al quale Turnstone è diventata una controllata interamente posseduta da XOMA Royalty Corporation, con XRA 3 Corp. come società di fusione sussidiaria. Di conseguenza, la registrante ha terminato le offerte previste dalle dichiarazioni di registrazione S-8 e ha rimosso le azioni invendute dalla registrazione in conformità ai suoi impegni precedenti. Gli emendamenti successivi all'efficacia sono stati firmati da Owen Hughes, Presidente, Tesoriere e Segretario.
Turnstone Biologics Corp. presentó enmiendas posteriores a la entrada en vigor para retirar y dar de baja de la inscripción todas las acciones no vendidas que permanecían registradas bajo dos declaraciones de registro del Formulario S-8. La compañía eliminó un total de 7,003,706 acciones no vendidas de la inscripción, correspondientes a acciones reservadas en su 2018 Equity Incentive Plan, 2023 Equity Incentive Plan y 2023 Employee Stock Purchase Plan.
La cancelación de la inscripción se produce tras un acuerdo de fusión por el cual Turnstone pasó a ser una subsidiaria totalmente propiedad de XOMA Royalty Corporation, con XRA 3 Corp. como filial de fusión. Como resultado, la registrante dio por terminadas las ofertas contempladas por las declaraciones de registro S-8 y retiró las acciones no vendidas de la inscripción, conforme a sus compromisos anteriores. Las enmiendas posteriores a la entrada en vigor fueron firmadas por Owen Hughes, Presidente, Tesorero y Secretario.
Turnstone Biologics Corp.는 두 건의 Form S-8 등록신고서에 여전히 등록되어 있던 모든 미판매 주식을 철회하고 등록을 말소하기 위한 효력 후 수정서(post-effective amendments)를 제출했습니다. 회사는 총 7,003,706주의 미판매 주식을 등록에서 말소했으며, 이는 2018 Equity Incentive Plan, 2023 Equity Incentive Plan 및 2023 Employee Stock Purchase Plan에 예약된 주식에 해당합니다.
이 등록 말소는 Turnstone이 XRA 3 Corp.를 합병 자회사로 하여 XOMA Royalty Corporation의 완전 자회사가 되는 합병계약에 따른 것입니다. 따라서 등록회사는 S-8 등록신고서에 따른 공모를 종료하고 이전의 약정에 따라 미판매 주식을 등록에서 제거했습니다. 효력 후 수정서는 Owen Hughes 사장 겸 재무 및 서기가 서명했습니다.
Turnstone Biologics Corp. a déposé des amendements post-efficacité pour retirer et radier de l'inscription toutes les actions invendues qui restaient enregistrées sous deux déclarations d'enregistrement au Formulaire S-8. La société a retiré au total 7,003,706 actions invendues de l'inscription, correspondant à des actions réservées dans ses 2018 Equity Incentive Plan, 2023 Equity Incentive Plan et 2023 Employee Stock Purchase Plan.
La radiation intervient après un accord de fusion par lequel Turnstone est devenue une filiale entièrement détenue par XOMA Royalty Corporation, XRA 3 Corp. agissant comme filiale de fusion. En conséquence, la société inscrite a mis fin aux offres prévues par les déclarations d'enregistrement S-8 et a retiré les actions invendues de l'inscription conformément à ses engagements antérieurs. Les amendements post-efficacité ont été signés par Owen Hughes, Président, Trésorier et Secrétaire.
Turnstone Biologics Corp. hat Nachträge nach dem Wirksamwerden eingereicht, um alle unveräußerten Aktien, die noch unter zwei Registrierungsformularen auf Form S-8 geführt wurden, zurückzuziehen und zu deregistrieren. Das Unternehmen strich insgesamt 7,003,706 unveräußerte Aktien aus der Registrierung, die im Rahmen seines 2018 Equity Incentive Plan, 2023 Equity Incentive Plan und 2023 Employee Stock Purchase Plan reserviert waren.
Die Deregistrierung erfolgt im Anschluss an eine Fusionsvereinbarung, aufgrund derer Turnstone eine vollständig im Eigentum von XOMA Royalty Corporation stehende Tochtergesellschaft wurde, wobei XRA 3 Corp. als Fusionstochter fungierte. Infolgedessen hat die registrierte Gesellschaft die in den S-8-Registrierungsformularen vorgesehenen Angebote eingestellt und die unveräußerten Aktien gemäß ihren früheren Verpflichtungen aus der Registrierung entfernt. Die nach dem Wirksamwerden eingereichten Nachträge wurden von Owen Hughes, Präsident, Schatzmeister und Sekretär, unterzeichnet.
- Merger completed: Turnstone became a wholly owned subsidiary of XOMA Royalty Corporation following the merger.
- Comprehensive deregistration: The company removed 7,003,706 unsold shares from registration across its equity plans, fulfilling its registration undertakings.
- Termination of offerings: The Registrant terminated all offerings of securities under the referenced Form S-8 registration statements.
- Registered equity pool removed: Shares previously available for grant or sale under the 2018 Plan, 2023 Plan and 2023 ESPP are no longer registered under those S-8 statements.
Insights
TL;DR: The company completed a merger and then removed unsold S-8 shares, terminating equity-plan offerings tied to the standalone registrant.
The Merger Sub was merged into Turnstone with Turnstone surviving as a wholly owned subsidiary of XOMA Royalty Corporation. Following that corporate change, Turnstone filed post-effective amendments to withdraw and terminate the effectiveness of its two Form S-8 registration statements, removing 7,003,706 unsold shares previously registered for issuance under the 2018 Plan, the 2023 Plan and the 2023 ESPP. This is a standard post-close corporate housekeeping step after a change in control that ends the registrant's separate securities offerings; it clarifies the pool of registered but unissued shares is no longer available under those registration statements.
TL;DR: Governance actions reflect termination of the registrant's standalone equity issuance capability after the acquisition.
Turnstone's post-effective amendments implement an undertaking in its S-8 filings to remove from registration any unsold securities when offerings terminate. The filing identifies the specific registrants and plans affected and documents that the company has terminated those offerings as it now operates as a wholly owned subsidiary of the acquiring parent. For stakeholders, this filing legally ends the registration status of the listed shares under the referenced S-8 statements and records the corporate change formally in SEC filings.
Turnstone Biologics Corp. ha depositato emendamenti successivi all'efficacia per ritirare e cancellare dalla registrazione tutte le azioni invendute che risultavano ancora registrate in due dichiarazioni di registrazione sul Modulo S-8. La società ha rimosso complessivamente 7,003,706 azioni invendute dalla registrazione, corrispondenti a titoli riservati nei suoi piani 2018 Equity Incentive Plan, 2023 Equity Incentive Plan e 2023 Employee Stock Purchase Plan.
La cancellazione dalla registrazione segue un accordo di fusione in base al quale Turnstone è diventata una controllata interamente posseduta da XOMA Royalty Corporation, con XRA 3 Corp. come società di fusione sussidiaria. Di conseguenza, la registrante ha terminato le offerte previste dalle dichiarazioni di registrazione S-8 e ha rimosso le azioni invendute dalla registrazione in conformità ai suoi impegni precedenti. Gli emendamenti successivi all'efficacia sono stati firmati da Owen Hughes, Presidente, Tesoriere e Segretario.
Turnstone Biologics Corp. presentó enmiendas posteriores a la entrada en vigor para retirar y dar de baja de la inscripción todas las acciones no vendidas que permanecían registradas bajo dos declaraciones de registro del Formulario S-8. La compañía eliminó un total de 7,003,706 acciones no vendidas de la inscripción, correspondientes a acciones reservadas en su 2018 Equity Incentive Plan, 2023 Equity Incentive Plan y 2023 Employee Stock Purchase Plan.
La cancelación de la inscripción se produce tras un acuerdo de fusión por el cual Turnstone pasó a ser una subsidiaria totalmente propiedad de XOMA Royalty Corporation, con XRA 3 Corp. como filial de fusión. Como resultado, la registrante dio por terminadas las ofertas contempladas por las declaraciones de registro S-8 y retiró las acciones no vendidas de la inscripción, conforme a sus compromisos anteriores. Las enmiendas posteriores a la entrada en vigor fueron firmadas por Owen Hughes, Presidente, Tesorero y Secretario.
Turnstone Biologics Corp.는 두 건의 Form S-8 등록신고서에 여전히 등록되어 있던 모든 미판매 주식을 철회하고 등록을 말소하기 위한 효력 후 수정서(post-effective amendments)를 제출했습니다. 회사는 총 7,003,706주의 미판매 주식을 등록에서 말소했으며, 이는 2018 Equity Incentive Plan, 2023 Equity Incentive Plan 및 2023 Employee Stock Purchase Plan에 예약된 주식에 해당합니다.
이 등록 말소는 Turnstone이 XRA 3 Corp.를 합병 자회사로 하여 XOMA Royalty Corporation의 완전 자회사가 되는 합병계약에 따른 것입니다. 따라서 등록회사는 S-8 등록신고서에 따른 공모를 종료하고 이전의 약정에 따라 미판매 주식을 등록에서 제거했습니다. 효력 후 수정서는 Owen Hughes 사장 겸 재무 및 서기가 서명했습니다.
Turnstone Biologics Corp. a déposé des amendements post-efficacité pour retirer et radier de l'inscription toutes les actions invendues qui restaient enregistrées sous deux déclarations d'enregistrement au Formulaire S-8. La société a retiré au total 7,003,706 actions invendues de l'inscription, correspondant à des actions réservées dans ses 2018 Equity Incentive Plan, 2023 Equity Incentive Plan et 2023 Employee Stock Purchase Plan.
La radiation intervient après un accord de fusion par lequel Turnstone est devenue une filiale entièrement détenue par XOMA Royalty Corporation, XRA 3 Corp. agissant comme filiale de fusion. En conséquence, la société inscrite a mis fin aux offres prévues par les déclarations d'enregistrement S-8 et a retiré les actions invendues de l'inscription conformément à ses engagements antérieurs. Les amendements post-efficacité ont été signés par Owen Hughes, Président, Trésorier et Secrétaire.
Turnstone Biologics Corp. hat Nachträge nach dem Wirksamwerden eingereicht, um alle unveräußerten Aktien, die noch unter zwei Registrierungsformularen auf Form S-8 geführt wurden, zurückzuziehen und zu deregistrieren. Das Unternehmen strich insgesamt 7,003,706 unveräußerte Aktien aus der Registrierung, die im Rahmen seines 2018 Equity Incentive Plan, 2023 Equity Incentive Plan und 2023 Employee Stock Purchase Plan reserviert waren.
Die Deregistrierung erfolgt im Anschluss an eine Fusionsvereinbarung, aufgrund derer Turnstone eine vollständig im Eigentum von XOMA Royalty Corporation stehende Tochtergesellschaft wurde, wobei XRA 3 Corp. als Fusionstochter fungierte. Infolgedessen hat die registrierte Gesellschaft die in den S-8-Registrierungsformularen vorgesehenen Angebote eingestellt und die unveräußerten Aktien gemäß ihren früheren Verpflichtungen aus der Registrierung entfernt. Die nach dem Wirksamwerden eingereichten Nachträge wurden von Owen Hughes, Präsident, Schatzmeister und Sekretär, unterzeichnet.
FAQ
What did Turnstone Biologics (TSBX) file with the SEC?
How many shares were removed from registration?
Which equity plans were affected by the deregistration?
Why were the securities deregistered?
When did the merger making Turnstone a subsidiary occur?
Who signed the post-effective amendments for Turnstone?
